CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Darbepoetin alfadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00883415
NCT00883415N/ACompleted
CompareCT.gov

A Study to Evaluate the Effect of the Treatment of Anemia on Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

University of Maryland, Baltimore·observational·Posted Apr 17, 2009·Updated May 21, 2020

In Brief

An observational study evaluating Darbepoetin alfa for Cardiomyopathy and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCardiomyopathy, Chronic Kidney Disease, Anemia
CountriesUnited States
CollaboratorsAmgen

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 17, 2009
Enrollment StartMay 1, 2008
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 17.2 years ago

Interventions

Darbepoetin alfadrug

Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol